Early Access — free while we kick the tires
EdgarHawk

Skvarka Jan

Director

Director
1 filing analyzed · 1 company · Latest 2025-02-04

Companies

Company Buys Sells Direction
Zentalis Pharmaceuticals, Inc. ZNTL 1 0 Net buying

Activity

February 2025
Buy
60,000 shares
$103,446
Significance 7/10

Director Skvarka buys 60,000 ZNTL shares at $1.72 amid cluster buy; stock -89.9% from 52-week high.

Director Jan Skvarka purchased 60,000 shares at $1.72 on 2025-01-31, expanding his holdings by 67.0% to 149,551 shares. This transaction is part of a cluster buy pattern, with 2 other insiders also purchasing within the past 14 days, suggesting aligned interest at the company level rather than isolated conviction. The context is stark: the stock trades at $1.63 (current price), down -89.9% from its 52-week high of $16.13, while the company reported zero quarterly revenue and a net loss of $-40,158,000.00 in its most recent period. This acquisition by a director during severe price depression and ongoing unprofitability warrants examination of whether board-level visibility into operational trajectory or financing initiatives informed the timing, though such visibility cannot be inferred from the transaction alone.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access